PATENT CLAIM ANALYSIS

Application Number: 16219418
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["424", "133100"]

Abstract:
The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).

Claim (Index 14):
A lipid nanoparticle comprising:\n (i) a first mRNA comprising an ORF encoding a human IL-23 polypeptide; (ii) a second mRNA comprising an ORF encoding a human IL-36 gamma polypeptide; and (iii) a third mRNA comprising an ORF encoding a human OX40L polypeptide, wherein each of the first, second, and third mRNAs are fully modified with chemically-modified uridines.

Metadata:
- Claim Count in Document: 80.0
- Percentile: 98.0
- Lexical Diversity: 1.73684
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['16184282', '15995889', '15996146', '16207575', '16192274']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7890703778283608
- 35 USC 102 Novelty (BERT): 0.6876795872335978
- Combined Prediction Score: 0.7789312987688846
- Mean Citation Score: 606.08613
- Max Citation Score: 776.2229
- Similarity Product: 670.2726373938559

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test